HIV Articles
Back
	Treatment for Key Groups: HIV Coinfection, African-Americans, Cirrhosis/Treatment Experiencec-PI-Failures, Decompensated Cirrhosis, Genotype 3, Post-Transplant       AASLD: Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV - (11/10/14) AASLD: TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir and Ribavirin - (11/12/14) AASLD: Safety and Efficacy of LDV/SOF in African Americans: A Retrospective Analysis of Phase 3 Data - (11/12/14) AASLD: Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Efficacious in Cirrhotic Patients Who Have Previously Failed Protease-Inhibitor Based Triple Therapy ± - (11/11/14)......97% of prior PI-failure patients with cirrhosis achieved SVR12......Similar SVR12 rates after 12 weeks of LDV/SOF with RBV compared with 24 weeks of LDV/SOF AASLD: An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin - (11/11/14)....96% of this group of 513 patients with compensated cirrhosis achieved an SVR......Among treatment-experienced patients, 12 weeks of LDV/SOF resulted in a 90% SVR rate.....Adding RBV or extending treatment duration increased this rate to ³96% AASLD: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study - (11/12/14) AASLD: High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection - (11/12/14) AASLD: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (11/11/14) AASLD: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post- Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study - (11/11/14) AASLD: HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION RECEIVING ABT-450/r/OMBITASVIR + DASABUVIR PLUS RIBAVIRIN - (11/12/14) CORAL-1 Study           View Older Articles   Back to Top   www.natap.org